Apollomics, Inc.
Apollomics, Inc.
- Market cap
- $147.80M
Your view on APLMW
Overview
What the company does, where it operates, and who runs it.
About Apollomics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Hung-Wen Chen
- Headquarters
- 989 East Hillsdale Blvd, Foster City, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Hung-Wen Chen
- Headquarters
- 989 East Hillsdale Blvd, Foster City, CA, US
Apollomics, Inc. functions as a clinical-phase biotechnology enterprise, concentrating its efforts on discovering and advancing novel cancer treatments to meet crucial, underserved patient requirements. The company was co-founded by Liang Yu Guo and Sanjeev Redkar in 2015, with its main operations based in Foster City, California.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Apollomics, Inc.. Starting points for Apollomics, Inc.: EPS -$3.32, beta 2.09 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Apollomics, Inc.. Trailing twelve-month EPS for Apollomics, Inc. stands at -$3.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|
| Average estimate | −$122.00 | −$138.00 |
| Lowest estimate | −$122.00 | −$138.00 |
| Highest estimate | −$122.00 | −$138.00 |
| Number of analysts | 1 | 1 |
| A year ago | −$7.571 | — |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|
| Average estimate | $237164.00 | $370045.00 |
| Lowest estimate | $237164.00 | $370045.00 |
| Highest estimate | $237164.00 | $370045.00 |
| Number of analysts | 1 | 1 |
| A year ago | $8.50M | — |
| Growth vs a year ago | −97.2% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Apollomics, Inc.. Apollomics, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AQFDClick To Raffle.Com, Inc. | Financial Services | Financial - Conglomerates | $3,024 | ||
| IMMGImmage Biotherapeutics Corp. | Financial Services | Financial - Conglomerates | $15,174 | ||
| KCPCKey Capital Corporation | Financial Services | Financial - Conglomerates | $4,602 | ||
| PGIEPGI Energy, Inc. | Energy | Oil & Gas Midstream | $20,222 | ||
| PLMKPlum Acquisition Corp. IV | Financial Services | Shell Companies | $258.2M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BETRFBetterLife Pharma Inc. | Healthcare | OTC | $6.4M | ||
| BHVNBiohaven Ltd. | Healthcare | NYSE | $1.9B | ||
| BICTFBiocure Technology Inc. | Healthcare | OTC | $379,088 | ||
| BIOABioAge Labs, Inc. | Healthcare | NASDAQ | $161.1M | ||
| BIOAFBioasis Technologies Inc. | Healthcare | OTC | $15,883 | ||
| BIORQBiora Therapeutics, Inc. | Healthcare | PNK | — | ||
| BIT.AXBiotron Limited | Healthcare | ASX | — | ||
| BITRFBiotron Limited | Healthcare | OTC | $29.2M | ||
| BIVIBioVie Inc. | Healthcare | NASDAQ | $8.6M | ||
| BIXTBioxytran, Inc. | Healthcare | OTC | $3.6M | ||
| BLAB.CNBritannia Life Sciences Inc. | Healthcare | CNQ | $13.0M | ||
| BLEGBranded Legacy Inc | Healthcare | OTC | $542,622 | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Apollomics, Inc., and how their positions are changing. At a $147.8M market value, institutional positions materially move Apollomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Apollomics, Inc. executives and directors. Shares of Apollomics, Inc. have traded between $0.01 and $0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Apollomics, Inc.